Published in PLoS One on February 20, 2009
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology (2010) 2.61
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42
HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog (2012) 1.70
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods (2013) 1.66
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods (2011) 1.40
Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog (2010) 1.36
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J Virol (2010) 1.21
Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A (2011) 1.16
A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis (2011) 1.15
Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA. J Virol (2011) 1.13
Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology (2010) 1.13
Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol (2011) 1.13
International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. PLoS One (2012) 1.12
Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production. AIDS Res Hum Retroviruses (2010) 1.08
sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Retrovirology (2010) 1.07
The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. PLoS One (2013) 1.05
Human erythrocytes selectively bind and enrich infectious HIV-1 virions. PLoS One (2009) 1.05
Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS (2010) 1.05
Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system. PLoS One (2013) 1.04
Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem (2012) 1.02
Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. J Virol (2012) 1.01
Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus. J Virol (2010) 1.01
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol (2011) 1.00
GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J Immunol (2010) 0.99
Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods (2014) 0.99
International network for comparison of HIV neutralization assays: the NeutNet report II. PLoS One (2012) 0.99
Kinetic mechanism for HIV-1 neutralization by antibody 2G12 entails reversible glycan binding that slows cell entry. Proc Natl Acad Sci U S A (2012) 0.97
Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes. J Virol (2011) 0.93
HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS One (2011) 0.93
Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol (2011) 0.90
HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity. PLoS One (2010) 0.87
Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients. PLoS One (2012) 0.87
Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. Int J Mol Sci (2012) 0.87
Cross-reactive broadly neutralizing antibodies: timing is everything. Front Immunol (2012) 0.86
Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge. PLoS One (2011) 0.83
Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. PLoS One (2015) 0.83
Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained. PLoS One (2011) 0.83
HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. PLoS One (2015) 0.82
Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010. J Transl Med (2011) 0.82
Challenges of antibody-mediated protection against HIV-1. Expert Rev Vaccines (2010) 0.81
An automated HIV-1 Env-pseudotyped virus production for global HIV vaccine trials. PLoS One (2012) 0.81
Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques. Vaccines (Basel) (2013) 0.81
Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology (2010) 0.81
UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J Virol (2012) 0.80
Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies. PLoS One (2011) 0.80
Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus. PLoS One (2012) 0.80
Statistical approaches to analyzing HIV-1 neutralizing antibody assay data. Stat Biopharm Res (2012) 0.78
Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. Retrovirology (2009) 0.78
Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. J Transl Med (2010) 0.78
Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice. Virology (2014) 0.78
Single-chain protein mimetics of the N-terminal heptad-repeat region of gp41 with potential as anti-HIV-1 drugs. Proc Natl Acad Sci U S A (2014) 0.78
Mechanisms of HIV-1 subtype C resistance to GRFT, CV-N and SVN. Virology (2013) 0.77
Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals. AIDS Res Hum Retroviruses (2012) 0.76
W-curve alignments for HIV-1 genomic comparisons. PLoS One (2010) 0.76
Automated image-based assay for evaluation of HIV neutralization and cell-to-cell fusion inhibition. BMC Infect Dis (2014) 0.75
Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles. Virol J (2011) 0.75
Hydroxytyrosol: a new class of microbicide displaying broad anti-HIV-1 activity. AIDS (2016) 0.75
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci U S A (1988) 6.74
Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature (1997) 6.23
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol (1997) 4.19
Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol (2004) 3.69
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis (1995) 3.25
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med (2002) 2.76
Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J Virol (2002) 2.44
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol (2004) 2.10
Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis (1999) 1.96
Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology (2008) 1.89
HIV vaccine failure prompts Merck to halt trial. Nature (2007) 1.87
Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. J Infect Dis (1993) 1.86
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol (2006) 1.65
Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol (1996) 1.59
Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun (2006) 1.58
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci U S A (1992) 1.54
Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS (1998) 1.42
Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. AIDS (1991) 1.42
Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J Virol (1996) 1.41
Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J Immunol (2004) 1.38
Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors. J Infect Dis (1997) 1.32
Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J Virol (2007) 1.14
A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol (2007) 1.12
HIV vaccine fails in phase 3 trial. Lancet (2003) 1.09
Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system. J Med Virol (2001) 1.09
A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res Hum Retroviruses (2002) 1.01
The role of the humoral immune response in HIV infection. AIDS (1996) 0.99
HIV vaccines: a global perspective. Curr Mol Med (2003) 0.97
Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study. AIDS Res Hum Retroviruses (1988) 0.97
HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies. AIDS Res Hum Retroviruses (2001) 0.92
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (2000) 0.92
Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays. J Virol Methods (2008) 0.92
Polymerase chain reaction-based assay for antibody-mediated neutralization of HIV-1 reveals a population of nonneutralized virus undetected by conventional p24 assay. J Acquir Immune Defic Syndr (2000) 0.91
Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases. J Med Virol (2003) 0.90
The World Health Organization Network for HIV Isolation and Characterization: summary of a pilot study. AIDS Res Hum Retroviruses (1994) 0.88
Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides. Antiviral Res (2007) 0.88
A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV Med (2008) 0.86
Plaque-reduction assays for human and simian immunodeficiency virus neutralization. Methods Mol Biol (2005) 0.83
Sensitivity of HIV type 1 primary isolates to human anti-CD40 antibody-mediated suppression is related to coreceptor use. AIDS Res Hum Retroviruses (2008) 0.79
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis (2008) 6.43
Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS (2011) 6.26
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS (2006) 5.31
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. Nat Cell Biol (2008) 4.34
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet (2005) 4.21
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother (2006) 4.14
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol (2005) 3.93
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis (2005) 3.91
The prevalence of antiretroviral drug resistance in the United States. AIDS (2004) 3.90
Possibility that transmissible viruses might be involved in the etiology of human cancer. Rev Clin Exp Hematol (2003) 3.76
Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther (2008) 3.53
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol (2006) 3.34
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure (2003) 3.32
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (2004) 3.31
The ecology and evolution of ant association in the Lycaenidae (Lepidoptera). Annu Rev Entomol (2002) 3.26
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis (2009) 2.75
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 2.70
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA (2010) 2.67
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS (2008) 2.65
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology (2010) 2.61
Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science (2013) 2.48
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med (2012) 2.48
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol (2002) 2.43
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS (2010) 2.33
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 2.29
Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis (2004) 2.29
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol (2011) 2.26
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Dangerous liaisons at the virological synapse. J Clin Invest (2004) 2.23
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol (2002) 2.23
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS (2006) 2.23
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother (2002) 2.21
Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med (2007) 2.20
Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS Res Hum Retroviruses (2007) 2.19
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med (2012) 2.12
The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J Virol (2004) 2.10
Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. Virology (2006) 2.07
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06
A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol (2006) 2.05
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis (2012) 2.05
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol (2007) 2.05
Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis (2004) 2.01
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis (2011) 1.99
Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol (2002) 1.97
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine (2006) 1.97
Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol (2002) 1.95
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 1.95
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89
Reproducibility of serologic assays for influenza virus A (H5N1). Emerg Infect Dis (2009) 1.88
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr (2007) 1.87
The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol (2003) 1.86
Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med (2006) 1.83